This study was done in collaboration with the Departments of Immunology and Nephrology at the University of Zurich, including Dr. Jakob Nilsson using the One Lambda Devyser Accept cfDNA assay. This is the first report on the use of an NGS assay to detect dd-cfDNA from multiple kidney transplants to monitor organ damage following transplantation. dd-cfDNA is used as a marker for monitoring organ damage and rejection following transplantation. Successfully differentiating dd-cfDNA in patients who have received a dual donor kidney transplant, or a sequential transplant, is a significant challenge in the accurate monitoring of such patients. This study showed that transplant patients had detectable cfDNA from multiple donor grafts and One Lambda Devyser Accept cfDNA was able to maintain a high sensitivity. The authors concluded that the results have the potential to influence clinical decision-making.

“It is fantastic that Devyser’s technology has the potential to improve monitoring and management of patients that have multiple kidney transplantations,” said Fredrik Alpsten, CEO at Devyser. “Devyser strives to innovate and be a pioneering leader of diagnostic solutions. We are proud to be part of making a difference for kidney transplanted patients.”

With about 92,000 kidney transplantations performed each year globally, significant numbers of patients need a second kidney transplant, requiring technologies that work when a patient has multiple kidneys from separate donors.

Follow the link below to read the article at the Frontier of Immunology: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1282521/full